Physician profile

Susan E Ring

Internal Medicine · Virginia Beach, VA

NPI 1790708667

$2,074.01

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $691.01 2019-2021
Astrazeneca Pharmaceuticals LP $395.51 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $199.79 2019-2020
Amgen INC. $155.10 2019-2021
Neurocrine Biosciences, INC. $128.54 2019
Tactile Systems Technology INC $104.57 2019
Novartis Pharmaceuticals Corporation $76.38 2020-2021
Amarin Pharma, INC. $71.00 2020-2021
Novo Nordisk INC $33.95 2019-2020
Mylan Specialty L.P. $32.42 2020-2021
Glaxosmithkline, LLC. $31.02 2019-2021
Merck Sharp & Dohme LLC $28.03 2021
Stimwave Technologies Incorporated $21.09 2019
Genzyme Corporation $16.77 2019
Takeda Pharmaceuticals U.S.A., INC. $15.31 2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Insulet Corporation $14.03 2019
Esperion Therapeutics, INC. $12.22 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $11.99 2020
Astellas Pharma US INC $11.97 2019
Lilly USA, LLC $11.78 2021
Kowa Pharmaceuticals America, INC. $11.53 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Susan E Ring

$2,074.01

in general payments reported 2019-2025

Years
2019-2021
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/307873/susan-e-ring

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.